Resource impact statement
No significant resource impact is anticipated
NICE has recommended Clearguard HD antimicrobial barrier caps for preventing catheter-related bloodstream infections in people with central venous catheters having haemodialysis.
The guidance is anticipated to be cost saving. This is because the additional cost of Clearguard HD antimicrobial barrier caps is offset by savings and benefits from reduced use of alternatives and a reduction in catheter-related bloodstream infections in people with central venous catheters having haemodialysis.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £1 million per year in England (or approximately £1,800 per 100,000 population, based on a population for England of 56.3 million people). This is based on a scenario for future practice in which ClearGuard HD antimicrobial barrier caps are assumed to occupy 25% market share alongside 3 existing comparators. However, due to the variability in infection rates and current and future use of the technology and the alternatives, a resource impact template is available to model different assumptions and local savings.
Renal replacement therapy services are commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: